Concerns over the clinical relevance and risk-worthiness of Puma Biotechnology Inc.'s Nerlynx (neratinib) in extended adjuvant use for women with early stage, HER2-positive breast cancer made it unlikely that the Europe's Committee for Medicinal Products for Human Use (CHMP) would support a marketing authorization application for the drug without "additional steps," Puma said.